Quantum BioPharma Submits MS Drug Candidate to UK ILAP Program
July 8th, 2025 2:09 PM
By: Newsworthy Staff
Quantum BioPharma Ltd. has submitted its multiple sclerosis drug candidate, Lucid-MS, to the UK's ILAP program, aiming to accelerate its development and patient access.
Quantum BioPharma Ltd. (NASDAQ: QNTM) announced the submission of its patented multiple sclerosis drug candidate, Lucid-21-302 (Lucid-MS), to the UK's Innovative Licensing and Access Pathway (ILAP) Passport program by its subsidiary, Huge Biopharma Australia Pty Ltd. The ILAP program is designed to fast-track the development and approval of innovative treatments by bringing together developers, regulators, and the NHS. Lucid-MS represents a novel approach to treating multiple sclerosis by targeting the disease's underlying mechanism of demyelination. This submission is a strategic move by Quantum BioPharma to expedite the clinical advancement and availability of Lucid-MS through regulatory pathways.
The ILAP program's goal is to streamline the process from development to patient access, making it a significant step for Quantum BioPharma in its mission to address neurodegenerative disorders. Lucid-MS has shown promise in preclinical models by preventing and reversing myelin degradation, which is crucial for the treatment of multiple sclerosis. For more details on the submission and the ILAP program, visit https://ibn.fm/giFkj.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
